Skip to main content

Table 1 Summary of in vivo RGC counts. Systemic and topical application of G-CSF or vehicle.

From: Both systemic and local application of Granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy

Experimental Group

Animal

RGCs per mm2

Mean

S.E.M.

axotomy + vehicle injection s.c.

1

360

  
 

2

348

  
 

3

594

  
 

4

379

420.6

58.4

axotomy + vehicle injection i.o.

1

443

  
 

2

390

  
 

3

378

  
 

4

435

  
 

5

365

402.2

15.5

axotomy + G-CSF 20 μg/kg BW s.c. daily

1

669

  
 

2

442

  
 

3

554

  
 

4

649

578.9

52.0

axotomy + G-CSF 40 μg/kg BW s.c. daily

1

729

  
 

2

637

  
 

3

778

  
 

4

704

  
 

5

773

742.3

25.8

axotomy + G-CSF 40 μg/kg BW s.c. daily (start 1 d before surgery)

1

641

  
 

2

876

  
 

3

696

  
 

4

872

771.3

60.3

axotomy + G-CSF 500 ng i.o. on days 0, 4, 7 and 10 after axotomy

1

638

  
 

2

613

  
 

3

773

  
 

4

703

681.8

35.8

  1. Cell numbers are given as mean ± S.E.M. s.c.: subcutaneous; i.o.: intraocular; BW: bodyweight.